Can magnesium applied as a foam to the skin of the leg prevent night leg cramps?

Effect of low pH magnesium sulfate foam on night leg cramps: A double-blind randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54352659

Enrollment

Registered

2018-11-29

Start date

2017-04-01

Completion date

Unknown

Last updated

2021-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Night leg cramps Musculoskeletal Diseases

Interventions

This was a home-based intervention within a Southeastern US urban community. Prior to enrolling participants in the study, all foam bottles were packaged by the manufacturer with the same label and sh

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years 2. Experiencing a minimum of 3 NLCs a week

Exclusion criteria

Exclusion criteria: 1. Patients nearing death 2. Taking medications causing NLCs 3. Adverse response to any topical foams 4. Allergy to magnesium or sulfur 5. Skin cuts 6. Active tissue or bone infections 7. Current foot or leg fractures

Design outcomes

Primary

Measure	Time frame
Number of NLCs per week during the 14 consecutive days of the intervention	—

Secondary

Measure	Time frame
1. Social function assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 2. Daily function assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 3. Sleep quality assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 4. Emotional well-being were assessed by using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 5. Daytime fatigue assessed using the Multi-Dimensional Fatigue Inventory at baseline and day 14	—

Measure

Time frame

1. Social function assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 2. Daily function assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 3. Sleep quality assessed using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 4. Emotional well-being were assessed by using the Restless Leg Syndrome Quality of Life Questionnaire at baseline and day 14 5. Daytime fatigue assessed using the Multi-Dimensional Fatigue Inventory at baseline and day 14

—

Countries

United States of America

Contacts

Public ContactToni Torres-McGehee

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026